Identification of fragile X syndrome specific molecular markers in human fibroblasts: A useful model to test the efficacy of therapeutic drugs

Daman Kumari, Aditi Bhattacharya, Jeffrey Nadel, Kristen Moulton, Nicole M. Zeak, Anne Glicksman, Carl Dobkin, David J. Brick, Philip H. Schwartz, Carolyn B. Smith, Eric Klann, Karen Usdin

Research output: Contribution to journalArticlepeer-review

Abstract

Fragile X syndrome (FXS) is the most frequent cause of inherited intellectual disability and autism. It is caused by the absence of the fragile X mental retardation 1 (FMR1) gene product, fragile X mental retardation protein (FMRP), an RNA-binding protein involved in the regulation of translation of a subset of brain mRNAs. In Fmr1 knockout mice, the absence of FMRP results in elevated protein synthesis in the brain as well as increased signaling of many translational regulators. Whether protein synthesis is also dysregulated in FXS patients is not firmly established. Here, we demonstrate that fibroblasts from FXS patients have significantly elevated rates of basal protein synthesis along with increased levels of phosphorylated mechanistic target of rapamycin (p-mTOR), phosphorylated extracellular signal regulated kinase 1/2, and phosphorylated p70 ribosomal S6 kinase 1 (p-S6K1). The treatment with small molecules that inhibit S6K1 and a known FMRP target, phosphoinositide 3-kinase (PI3K) catalytic subunit p110β, lowered the rates of protein synthesis in both control and patient fibroblasts. Our data thus demonstrate that fibroblasts from FXS patients may be a useful in vitro model to test the efficacy and toxicity of potential therapeutics prior to clinical trials, as well as for drug screening and designing personalized treatment approaches. We show that primary fibroblasts from fragile X syndrome (FXS) patients have elevated rates of protein synthesis and increased levels of translational regulators, p-mTOR and p-S6K1. Treatment with inhibitors of S6K1 and PI3K reduces rates of protein synthesis in these cells. Our data suggest that primary fibroblasts from FXS patients can be a useful cell-based model for high-throughput drug screens, evaluation of potential therapeutic compounds and designing personalized treatment approaches.

Original languageEnglish (US)
Pages (from-to)1485-1494
Number of pages10
JournalHuman Mutation
Volume35
Issue number12
DOIs
StatePublished - Dec 1 2014

Keywords

  • FMR1
  • FMRP
  • Fibroblasts
  • Fragile X syndrome
  • Protein synthesis
  • S6K1

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Identification of fragile X syndrome specific molecular markers in human fibroblasts: A useful model to test the efficacy of therapeutic drugs'. Together they form a unique fingerprint.

Cite this